This Advisory, based on TIP 49, Incorporating Alcohol Pharmacotherapies Into Medical Practice, focuses on medication and related treatment decisions made after screening and assessment for AUD, and medically supervised withdrawal, if necessary. Alcohol consumption should not stop abruptly in those patients who have consumed alcohol regularly over a prolonged period of time. This Advisory is meant as an overview of AUD medications to facilitate abstinence.

This manual provides clinical practice guidelines for using medications in the medication-assisted treatment of alcohol use disorder. It offers guidance on prescribing acamprosate, disulfiram, oral naltrexone, and extended-release injectable naltrexone. The manual also discusses patient management. Access the literature review.

This manual offers guidance and tools for identifying mental illness or substance use issues early in children and adolescents in various setting, such as in schools, the juvenile justice and child welfare system, and when receiving primary care.

This guide helps substance use counselors treat clients with symptoms of depression and substance use conditions. Program administrators will learn how to integrate depression treatment into early drug treatment. The guidelines cover screening, assessment, treatment, counseling, cultural competence, and continuing care. 

This manual provides physicians with quick reference information about three FDA-approved medications to help patients achieve abstinence from alcohol: acamprosate, disulfiram, and naltrexone (oral and extended-release). It also includes patient management tips.

This manual guides physicians in the use of medications to help patients achieve abstinence from alcohol. It describes how the medications work, whom they benefit, and side effects for three FDA-approved medications: acamprosate, disulfiram, and naltrexone.